A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular Disease

Cardiovasc Drugs Ther. 2023 Dec;37(6):1167-1174. doi: 10.1007/s10557-021-07313-9. Epub 2022 Jan 14.

Abstract

Cardiovascular risk has traditionally been defined by modifiable and non-modifiable risk factors, such as tobacco use, hyperlipidemia, and family history. However, chemicals and pollutants may also play a role in cardiovascular disease (CVD) risk. Arsenic is a naturally occurring element that is widely distributed in the Earth's crust. Inorganic arsenic (iAs) has been implicated in the pathogenesis of atherosclerosis, with chronic high-dose exposure to iAs (> 100 µg/L) being linked to CVD; however, whether low-to-moderate dose exposures of iAs (< 100 µg/L) are associated with the development of CVD is unclear. Due to limitations of the existing literature, it is difficult to define a threshold for iAs toxicity. Studies demonstrate that the effect of iAs on CVD is far more complex with influences from several factors, including diet, genetics, metabolism, and traditional risk factors such as hypertension and smoking. In this article, we review the existing data of low-to-moderate dose iAs exposure and its effect on CVD, along with highlighting the potential mechanisms of action.

Keywords: Arsenic; Atherosclerosis; Cardiovascular disease; Cardiovascular toxicity; Mechanism of action.

Publication types

  • Review

MeSH terms

  • Arsenic* / toxicity
  • Arsenicals*
  • Atherosclerosis* / chemically induced
  • Atherosclerosis* / epidemiology
  • Cardiovascular Diseases* / chemically induced
  • Cardiovascular Diseases* / epidemiology
  • Humans
  • Risk Factors

Substances

  • Arsenic
  • Arsenicals